CHRDL1

Across TCGA pan-cancer cohorts, CHRDL1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated CHRDL1 data layer compared with 6 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CHRDL1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRDL1 expression acts as an unfavorable survival marker, although some lineages such as MESO and LUAD show a favorable association.

BLCA, MESO, and LUSC are the cancer types where CHRDL1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	0.550	0.694	<.001	98	view →
MESO	DFS	Tertile	All	0.526	0.262	.001	74	view →
LUSC	OS	Quartile	All	0.300	0.484	<.001	64	view →
LUAD	OS	Median	All	0.751	0.623	<.001	63	view →
KIRC	OS	Quartile	All	0.717	0.878	<.001	59	view →
SKCM	DFS	Median	All	0.246	0.145	.001	52	view →
UVM	DFS	Median	All	0.459	0.992	<.001	35	view →
STAD	OS	Quartile	All	0.505	0.688	.007	19	view →
UCEC	DFS	Quartile	All	0.845	0.946	<.001	12	view →
CHOL	DFS	Tertile	II,III,IV	0.838	0.135	.020	11	view →
LIHC	OS	Tertile	III,IV	0.515	0.896	.012	11	view →
THCA	OS	Quartile	II,III,IV	0.821	1.000	.023	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

CHRDL1–BLCA (DFS)

Open the BLCA breakdown →